Abstract:The biomarker CA125, a peptide epitope located in several tandem repeats of the mucin MUC16, is the gold standard for monitoring regression and recurrence of high-grade serous ovarian cancer in response to therapy. However, the CA125 epitope along with several structural features of the MUC16 molecule are ill defined. One central aspect still unresolved is the number of tandem repeats in MUC16 and how many of these repeats contain the CA125 epitope. Studies from the early 2000s assembled short DNA reads to estimate that MUC16 contained 63 repeats.Here, we conduct Nanopore long-read sequencing of MUC16 transcripts from three primary ovarian tumors and established cell lines (OVCAR3, OVCAR5, and Kuramochi) for a more exhaustive and accurate estimation and sequencing of the MUC16 tandem repeats.The consensus sequence derived from these six sources was confirmed by proteomics validation and agrees with recent additions to the NCBI database. We propose a model of MUC16 containing 19-not 63-tandem repeats. In addition, we predict the structure of the tandem repeat domain using the deep learning algorithm, AlphaFold.The predicted structure displays an SEA domain and unstructured linker region rich in proline, serine, and threonine residues in all 19 tandem repeats. These studies now pave the way for a detailed characterization of the CA125 epitope. Sequencing and modeling of the MUC16 tandem repeats along with their glycoproteomic characterization, currently underway in our laboratories, will help identify novel epitopes in the MUC16 molecule that improve on the sensitivity and clinical utility of the current CA125 assay. Significance: Despite its crucial role in clinical management of ovarian cancer, the exact molecular sequence and structure of the biomarker, CA125, are not defined. Here, we combine long-read sequencing, mass spectrometry, and in silico modeling to provide the foundational dataset for a more complete characterization of the CA125 epitope.

MUC16/CA125 in cancer: new advances

Update value and clinical application of MUC16 (cancer antigen 125)

The Clinical Utility of CA125/MUC16 in Pancreatic Cancer: A Consensus of Diagnostic, Prognostic and Predictive Updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

Targeting MUC16 in Cancer Therapy

C-terminus of MUC16 Activates Wnt Signaling Pathway Through Its Interaction with Β-Catenin to Promote Tumorigenesis and Metastasis

The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia.

Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells

MUC1 and MUC16: critical for immune modulation in cancer therapeutics

Targeting MUC15 Protein in Cancer: Molecular Mechanisms and Therapeutic Perspectives

Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma

Mucin Glycans: A Target for Cancer Therapy

MUC21: a new target for tumor treatment

Mucin1 As a Potential Molecule for Cancer Immunotherapy and Targeted Therapy.

The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity

A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing

Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies

Carboxyl-terminal polypeptide fragment of MUC16 combing stathmin1 promotes gallbladder cancer cell migration and invasion

Crystal structure of a human MUC16 SEA domain reveals insight into the nature of the CA125 tumor marker

High Mutation Load, Immune-Activated Microenvironment, Favorable Outcome, and Better Immunotherapeutic Efficacy in Melanoma Patients Harboring MUC16/CA125 Mutations

MUC16 mutations improve patients’ prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment

Advances in Research of Cancer Vaccines Targeting Mucin-1